The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
Stephanie Heon
No relevant relationships to disclose
Mizuki Nishino
No relevant relationships to disclose
Sarah B. Goldberg
No relevant relationships to disclose
Jennifer Porter
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; Millennium; Pfizer
Stock Ownership - Celgene
Other Remuneration - Genzyme